Axsome Therapeutics, Inc. (AXSM) Institutional Ownership & Insider Trading

503 institutions reported holding Axsome Therapeutics, Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 36 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

AXSMAxsome Therapeutics, Inc.Follow AXSM — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 7.6B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 2 Nov, in 9 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

503 institutions held 73.8% of the shares. Across filers that reported both quarters, shares held changed +0.4%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	503	39	+0.4%	148	120	146	31
Mar 26	408	38	+2.4%	129	55	127	42
Dec 25	391	38	-3.2%	130	58	111	24
Sep 25	347	37	+0.4%	130	40	93	31
Jun 25	341	38	+0.7%	142	43	82	49
Mar 25	348	37	+1.8%	96	84	101	26
Dec 24	287	37	-4.3%	84	46	78	35
Sep 24	274	38	-6.8%	72	40	83	21

Axsome Therapeutics, Inc. — questions

Who owns Axsome Therapeutics, Inc. stock?: 503 institutions reported Axsome Therapeutics, Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: BlackRock, Inc. (5.9%), VANGUARD PORTFOLIO MANAGEMENT LLC (3.8%), VANGUARD CAPITAL MANAGEMENT LLC (3.8%).
Are Axsome Therapeutics, Inc. insiders buying or selling?: 36 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Axsome Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.